Joseph Ciccolini, Pharm.D. Ph.D. - La Timone University Hospital of Marseille - Dr

Joseph Ciccolini

Pharm.D. Ph.D.

La Timone University Hospital of Marseille

Dr

Marseille | France

Main Specialties: Oncology

Additional Specialties: Pharmacokinetics, Oncology

Joseph Ciccolini, Pharm.D. Ph.D. - La Timone University Hospital of Marseille - Dr

Joseph Ciccolini

Pharm.D. Ph.D.

Introduction

Primary Affiliation: La Timone University Hospital of Marseille - Marseille , France

Specialties:

Additional Specialties:

Education

May 2000
AMU
PhD
Dec 1994
AMU
PharmD

Publications

86Publications

2081Reads

-Profile Views

496PubMed Central Citations

In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling.

Sci Rep 2016 11 4;6:36173. Epub 2016 Nov 4.

Pharmacokinectics Laboratory, SMARTc Unit, Inserm S_911 CrO2, Aix-Marseille Univ, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep36173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095884PMC
November 2016
4 Reads
4 Citations
5.080 Impact Factor

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations.

Anticancer Res 2016 11;36(11):6051-6057

UMR CNRS 8612, Galien Institute, Faculty of Pharmacy, University Paris-Saclay, Châtenay-Malabry, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11194DOI Listing
November 2016
121 Reads
1.872 Impact Factor

Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.

Cancer Res 2016 09 14;76(17):4931-40. Epub 2016 Jun 14.

Aix Marseille University, SMARTc Unit, Inserm S 911 CRO2, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-3567DOI Listing
September 2016
27 Reads
13 Citations
9.330 Impact Factor

Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.

Clin Pharmacokinet 2016 08;55(8):1015-25

Pharmacokinetics Unit, Faculty of Pharmacy, Aix Marseille University, SMARTc, Inserm CRO2 UMR_S 911, 27, bd. Jean Moulin, CS 30064, 13385, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0374-7DOI Listing
August 2016
17 Reads
5 Citations
5.053 Impact Factor

Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.

Biomark Insights 2016 16;11:105-11. Epub 2016 Aug 16.

Laboratory of Biochemistry, Faculty of Medicine, Badji Mokhtar University, Annaba, Algeria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BMI.S33372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993165PMC
August 2016
24 Reads
1 Citation

Nucleoside analogs: ready to enter the era of precision medicine?

Expert Opin Drug Metab Toxicol 2016 Aug 30;12(8):865-77. Epub 2016 May 30.

a SMARTc Unit , Inserm S_911 CRO2 Aix-Marseille University , Marseille , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2016.1192128DOI Listing
August 2016
9 Reads
2 Citations
2.831 Impact Factor

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.

Cancer Chemother Pharmacol 2016 07 23;78(1):1-12. Epub 2016 Mar 23.

Department of Medical Oncology, VUmc, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3003-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921117PMC
July 2016
19 Reads
17 Citations
2.770 Impact Factor

Monoclonal antibodies for treating gastric cancer: promises and pitfalls.

Expert Opin Biol Ther 2016 06 25;16(6):759-69. Epub 2016 Mar 25.

a Department of Digestive Oncology , Aix-Marseille University - Assistance Publique Hôpitaux de Marseille , Marseille , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2016.1164137DOI Listing
June 2016
20 Reads
3.743 Impact Factor

Women at a Disadvantage in Fluorouracil Treatment.

JAMA Oncol 2016 Jun;2(6):829-30

Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.1086DOI Listing
June 2016
11 Reads
2 Citations

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.

BMC Cancer 2016 Apr 20;16:278. Epub 2016 Apr 20.

Multidisciplinary Oncology and Therapeutic Innovations department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2308-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837593PMC
April 2016
30 Reads
8 Citations
3.362 Impact Factor

Computational oncology--mathematical modelling of drug regimens for precision medicine.

Nat Rev Clin Oncol 2016 Apr 24;13(4):242-54. Epub 2015 Nov 24.

Aix Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13005, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.204DOI Listing
April 2016
43 Reads
19 Citations
14.180 Impact Factor

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.

Br J Clin Pharmacol 2016 Jan 28;81(1):124-30. Epub 2015 Nov 28.

Digestive Oncology Unit, La Timone University Hospital of Marseille, Marseille.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693577PMC
January 2016
28 Reads
6 Citations
3.880 Impact Factor

DPD deficiency in patients treated with fluorouracil.

Authors:
Joseph Ciccolini

Lancet Oncol 2015 Dec 23;16(16):1574-6. Epub 2015 Oct 23.

Clinical Pharmacokinetics Laboratory, La Timone University Hospital of Marseille, 13385 Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00360-5DOI Listing
December 2015
11 Reads
1 Citation
24.690 Impact Factor

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Semin Cancer Biol 2015 Dec 7;35:53-61. Epub 2015 Sep 7.

Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2015.09.002DOI Listing
December 2015
18 Reads
8 Citations
9.330 Impact Factor

[Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs].

Ann Biol Clin (Paris) 2014 Sep-Oct;72(5):527-42

Service de pharmacocinétique et toxicologie, Laboratoire de biologie médicale, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2014.0993DOI Listing
November 2015
6 Reads
1 Citation
0.420 Impact Factor

Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.

Pharmacogenomics 2015 Nov 10;16(17):1907-12. Epub 2015 Nov 10.

Onco-Hematology Unit, La Conception University Hospital of Marseille, APHM, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.15.135DOI Listing
November 2015
35 Reads
3 Citations
3.220 Impact Factor

Trastuzumab-induced cardiotoxicity: is it a personalized risk?

Curr Drug Targets 2014 ;15(13):1200-4

Head Oncopharmacology Unit and EA UNS 3836, Centre Antoine Lacassagne, 33 Av Valombrose, 06189 Nice Cedex 2, France.

View Article

Download full-text PDF

Source
August 2015
22 Reads
1 Citation
3.021 Impact Factor

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.

Proc Natl Acad Sci U S A 2015 Jul 16;112(27):E3453. Epub 2015 Jun 16.

SMARTc Unit, Pharmacokinetics Laboratory, Inserm S_911 CRO2 Aix Marseille University, and La Timone University Hospital of Marseille, 13000 Marseille, France; Multidisciplinary Oncology and Therapeutic Innovations Unit, Nord University Hospital of Marseille, 13000 Marseille, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1506689112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500227PMC
July 2015
16 Reads
4 Citations
9.810 Impact Factor

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Pharmacogenet Genomics 2015 Jun;25(6):317-21

aSMARTc Unit, Pharmacokinetics Laboratory, UMR_911 CRO2 AMU bPharmacy Unit cOnco-Hematology Unit dHematology Laboratory, La Conception University Hospital of Marseille eTransfer Oncology Laboratory, Nord University Hospital of Marseille, APHM, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000139DOI Listing
June 2015
17 Reads
3.481 Impact Factor

Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.

Expert Opin Drug Metab Toxicol 2015 May 13;11(5):665-72. Epub 2014 Dec 13.

INSERM UMR_S911 Aix-Marseille University, SMARTc, CRO2, Pharmacokinetics Unit , UFR Pharmacie 27 Bd Jean Moulin 13385 Marseille , France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2015.985648DOI Listing
May 2015
8 Reads
8 Citations
2.831 Impact Factor

Pharmacogenetics and breast cancer management: current status and perspectives.

Expert Opin Drug Metab Toxicol 2015 May 18;11(5):719-29. Epub 2015 Feb 18.

SMARTc Pharmacokinetics Unit, UMR S_911 CRO2, AMU , Marseille , France.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/17425255.2015.10
Publisher Site
http://dx.doi.org/10.1517/17425255.2015.1008447DOI Listing
May 2015
16 Reads
3 Citations
2.831 Impact Factor

Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.

Nucleosides Nucleotides Nucleic Acids 2014 ;33(4-6):403-12

a Department of Medical Oncology , VU University Medical Center , Amsterdam , The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15257770.2014.894196DOI Listing
February 2015
42 Reads
3 Citations
1.020 Impact Factor

Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter.

Clin Cancer Res 2015 Feb;21(4):934

Aix Marseille University, Simulation and Modelling, Adaptive Response for Therapeutics in Cancer (SMARTc), Inserm U911 CRO2, Marseille, France. Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2832DOI Listing
February 2015
11 Reads
8.722 Impact Factor

Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice.

Cancer Res 2014 Nov 12;74(22):6397-407. Epub 2014 Sep 12.

I2M UMR 7373 Aix-Marseille Université, CNRS, Centrale Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0721DOI Listing
November 2014
33 Reads
18 Citations
9.330 Impact Factor

Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?

Pharmacogenet Genomics 2014 Oct;24(10):527-9

aTransfert Oncology Unit, Nord Hospital bSurgery Unit, La Timone Hospital cPediatric Oncology Unit, La Timone Hospital dUMR S 911 - CRO2, Aix-Marseille Université, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000076DOI Listing
October 2014
60 Reads
2 Citations
3.481 Impact Factor

Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters.

Pharm Res 2014 Oct 22;31(10):2677-84. Epub 2014 Apr 22.

Pharmacokinetics Unit, UMR S_911, CRO2, Aix Marseille University, Marseille, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-014-1364-9DOI Listing
October 2014
14 Reads
3 Citations
3.420 Impact Factor

Metronomics chemotherapy: time for computational decision support.

Cancer Chemother Pharmacol 2014 Sep 1;74(3):647-52. Epub 2014 Aug 1.

SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2 Aix-Marseille University, 27 Bd Jean Moulin, 13385, Marseille 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2546-1DOI Listing
September 2014
14 Reads
9 Citations
2.770 Impact Factor

Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs.

Crit Rev Oncol Hematol 2013 Dec 18;88(3):504-13. Epub 2013 Jul 18.

Hospital Pharmacy Unit, La Conception University Hospital of Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.06.010DOI Listing
December 2013
7 Reads
8 Citations
4.030 Impact Factor

Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.

Pharmacogenomics 2013 Jul;14(9):1047-51

Transfer Oncology Laboratory, Nord University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.13.93DOI Listing
July 2013
41 Reads
7 Citations
3.220 Impact Factor

Gender, cytidine deaminase, and 5-aza/decitabine--letter.

Clin Cancer Res 2013 Jun 8;19(11):3105. Epub 2013 May 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0483DOI Listing
June 2013
14 Reads
1 Citation
8.722 Impact Factor

Personalized medicine in oncology: where have we come from and where are we going?

Pharmacogenomics 2013 Jun;14(8):931-9

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.13.79DOI Listing
June 2013
18 Reads
9 Citations
3.220 Impact Factor

Optimization of trans-Resveratrol bioavailability for human therapy.

Biochimie 2013 Jun 31;95(6):1233-8. Epub 2013 Jan 31.

University Aix Marseille, INRA UMR 1260, 13385 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biochi.2013.01.008DOI Listing
June 2013
19 Reads
17 Citations
2.963 Impact Factor

In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity.

Pharm Res 2013 May 6;30(5):1281-90. Epub 2013 Feb 6.

Pharmacokinetics Unit, School of Pharmacy, Aix Marseille University, Inserm U911 Cro-2, 27 Bd Jean Moulin, 13385, Marseille, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs11095-012-09
Web Search
http://link.springer.com/10.1007/s11095-012-0967-2
Publisher Site
http://dx.doi.org/10.1007/s11095-012-0967-2DOI Listing
May 2013
13 Reads
1 Citation
3.420 Impact Factor

Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.

Curr Top Med Chem 2012 ;12(15):1713-9

UMR-MD3, Aix-Marseille Univ, 13375 Marseille, France.

View Article

Download full-text PDF

Source
April 2013
8 Reads
3 Citations
3.402 Impact Factor

100% human monoclonal antibodies in oncology: hype or breakthrough?

Curr Top Med Chem 2012 ;12(15):1643-8

Laboratoire de Pharmacocinetique - UFR Pharmacie, 27 Bd Jean Moulin, 13385 Marseille, France.

View Article

Download full-text PDF

Source
April 2013
11 Reads
1 Citation
3.402 Impact Factor

Editorial: targeted therapy, targeted dosing and targeted delivery in oncology: where do we stand?

Authors:
Joseph Ciccolini

Curr Top Med Chem 2012 ;12(15):1638

View Article

Download full-text PDF

Source
April 2013
6 Reads
1 Citation
3.402 Impact Factor

Severe or lethal toxicities with nucleosidic analogs: time for action.

Pharmacogenomics 2013 Feb;14(3):227-30

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.208DOI Listing
February 2013
9 Reads
2 Citations
3.220 Impact Factor

Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.

ISRN Pharm 2012 9;2012:738432. Epub 2012 Feb 9.

UMR 911 CRO2, Pharmacokinetics Laboratory, Aix-Marseille University, 13385 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5402/2012/738432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302123PMC
August 2012
32 Reads
8 Citations

Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.

Fundam Clin Pharmacol 2012 Aug 30;26(4):530-7. Epub 2011 May 30.

Oncopharmacology Unit, Centre Antoine Lacassagne, 06189 Nice, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1472-8206.2011.00945.xDOI Listing
August 2012
22 Reads
2.080 Impact Factor

CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations.

Pharmacogenomics 2012 Mar;13(4):393-7

Laboratoire de Pharmacocinétique, La Timone University Hospital of Marseille, UMR 911, Aix-Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.11.175DOI Listing
March 2012
24 Reads
2 Citations
3.220 Impact Factor

Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.

J Clin Oncol 2012 Feb 19;30(4):e41-4. Epub 2011 Dec 19.

La Timone University Hospital of Marseille, Aix-Marseille Univ, CRO2 UMR 911, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.37.9289DOI Listing
February 2012
42 Reads
1 Citation
18.430 Impact Factor

A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.

Clin Cancer Res 2012 Jan;18(1):317

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1360DOI Listing
January 2012
10 Reads
1 Citation
8.722 Impact Factor

5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.

Cancer Chemother Pharmacol 2011 Sep 8;68(3):823-6. Epub 2011 May 8.

Hôpital d'Instruction des Armées Laveran, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1666-0DOI Listing
September 2011
16 Reads
5 Citations
2.770 Impact Factor

Integrating pharmacogenetics into gemcitabine dosing--time for a change?

Nat Rev Clin Oncol 2011 02 8;8(7):439-44. Epub 2011 Feb 8.

Pôle Oncologie, La Timone University Hospital of Marseille, 267 Rue St Pierre, 13385 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.1DOI Listing
February 2011
11 Reads
8 Citations
14.180 Impact Factor

Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?

Clin Colorectal Cancer 2010 Oct;9(4):224-8

La Timone University Hospital, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2010.n.033DOI Listing
October 2010
36 Reads
13 Citations
2.910 Impact Factor

High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.

Ther Drug Monit 2010 Feb;32(1):53-60

Laboratoire de Biochimie, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0b013e3181c77c1bDOI Listing
February 2010
15 Reads
3 Citations
2.380 Impact Factor

Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.

Cancer Chemother Pharmacol 2009 May 24;63(6):1177-80. Epub 2008 Dec 24.

Medical Oncology Unit, La Timone University Hospital, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-008-0889-1DOI Listing
May 2009
12 Reads
6 Citations
2.770 Impact Factor

Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression.

PLoS One 2009 6;4(2):e4409. Epub 2009 Feb 6.

EA 4263, Therapy of Genetic Disorder, Faculté de Médecine de la Timone, Marseille, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004409PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634969PMC
March 2009
24 Reads
21 Citations
3.234 Impact Factor

Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells.

Phytother Res 2008 Oct;22(10):1299-302

Laboratory of Pharmacognosy, UMR-D3, Faculty of Pharmacy, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ptr.2483DOI Listing
October 2008
13 Reads
3 Citations
2.400 Impact Factor

Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines.

Planta Med 2008 Aug 29;74(10):1265-8. Epub 2008 Jul 29.

Laboratory of Pharmacokinetics and Toxicokinetics, EA3286, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2008-1081298DOI Listing
August 2008
17 Reads
2.152 Impact Factor

Validation of a simple HPLC method for assay of haplamine and its metabolites in plasma suitable for pharmacokinetic application in rats.

Biomed Chromatogr 2008 Feb;22(2):125-30

Laboratory of Pharmacokinetics and Toxicokinetics, EA 3286, Faculty of Pharmacy, University of Mediterranee, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.904DOI Listing
February 2008
16 Reads
1.723 Impact Factor

Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?

Trends Pharmacol Sci 2007 Dec 14;28(12):597-8. Epub 2007 Nov 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2007.09.009DOI Listing
December 2007
13 Reads
7 Citations
11.540 Impact Factor

Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.

J Clin Oncol 2007 Oct;25(30):4855; author reply 4855-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.3918DOI Listing
October 2007
18 Reads
3 Citations
18.430 Impact Factor

Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.

Clin Colorectal Cancer 2006 Nov;6(4):288-96

EA3286, Medical Oncology Unit, La Timone University Hospital, Marseille, France.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S153300281170475
Publisher Site
http://dx.doi.org/10.3816/CCC.2006.n.047DOI Listing
November 2006
14 Reads
7 Citations
2.910 Impact Factor

Pharmacogenetics of capecitabine in advanced breast cancer patients.

Clin Cancer Res 2006 Sep;12(18):5496-502

Centre Antoine Lacassagne, Nice, and Pharmacokinetic Unit, La Timone University Hospital, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0320DOI Listing
September 2006
36 Reads
22 Citations
8.722 Impact Factor

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

Cancer Chemother Pharmacol 2006 Aug 15;58(2):272-5. Epub 2005 Nov 15.

Clinical Pharmacokinetics Department, La Timone University Hospital, Marseille, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-005-0139-8
Publisher Site
http://dx.doi.org/10.1007/s00280-005-0139-8DOI Listing
August 2006
16 Reads
9 Citations
2.770 Impact Factor

Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.

Anticancer Drugs 2006 Aug;17(7):807-13

Centre Antoine-Lacassagne, Department of Oncopharmacology, Nice Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000224444.23953.90DOI Listing
August 2006
18 Reads
1 Citation
1.891 Impact Factor

Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study.

Anticancer Drugs 2006 Apr;17(4):463-70

Pharmacokinetics Department, School of Pharmacy, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000198914.83195.61DOI Listing
April 2006
14 Reads
2 Citations
1.891 Impact Factor

Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.

Pharm Res 2005 Dec 21;22(12):2051-7. Epub 2005 Oct 21.

Laboratoire de Pharmacocinétique, UFR Pharmacie, 27 Bd Jean Moulin, 13385, Marseille cedex 05, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11095-005-8355
Web Search
http://link.springer.com/10.1007/s11095-005-8355-9
Publisher Site
http://dx.doi.org/10.1007/s11095-005-8355-9DOI Listing
December 2005
11 Reads
3 Citations
3.420 Impact Factor

Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.

Mol Cancer Ther 2005 Dec;4(12):1962-71

Oncopharmacology Unit, Centre Antoine-Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-05
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-05-0108DOI Listing
December 2005
8 Reads
4 Citations
5.683 Impact Factor

Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs.

Anticancer Drugs 2005 Jul;16(6):675-82

Laboratory of Pharmacokinetics and Toxicokinetics, Faculty of Pharmacy, Marseille, France.

View Article

Download full-text PDF

Source
July 2005
72 Reads
1 Citation
1.891 Impact Factor

Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.

Anticancer Drugs 2005 Mar;16(3):309-16

Centre Antoine-Lacassagne, Nice, France.

View Article

Download full-text PDF

Source
March 2005
14 Reads
1 Citation
1.891 Impact Factor

Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.

Anticancer Drugs 2004 Nov;15(10):969-74

Centre Antoine-Lacassagne, Nice, France; Pharmacy School, Marseille, France.

View Article

Download full-text PDF

Source
November 2004
57 Reads
6 Citations
1.891 Impact Factor

Enzyme-prodrug systems: thymidine phosphorylase/5'-deoxy-5-fluorouridine.

Methods Mol Med 2004 ;90:263-78

Department of Toxicology, Faculty of Pharmacy, University of Montpellier, Montpellier, France.

View Article

Download full-text PDF

Source
March 2004
19 Reads
1 Citation

Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.

Curr Med Chem Anticancer Agents 2004 Mar;4(2):71-81

Laboratoire de Pharma-cocinétique, Faculté de Pharmacie, 27 Bd Jean Moulin 13385 Marseille Cedex 05.

View Article

Download full-text PDF

Source
March 2004
7 Reads
10 Citations

[Dosage regimen optimization in cancer chemotherapy using a mathematical model].

Bull Cancer 2003 Feb;90(2):167-75

Service d'Oncologie Médicale, Centre Hospitalier Lyon-Sud, 69000 Lyon, France.

View Article

Download full-text PDF

Source
February 2003
6 Reads
1 Citation
0.640 Impact Factor

Population pharmacokinetics of etoposide: application to therapeutic drug monitoring.

Ther Drug Monit 2002 Dec;24(6):709-14

Fédération de Pharmacologie Médicale et Clinique et de Pharmacocinétique, Marseille, France.

View Article

Download full-text PDF

Source
December 2002
37 Reads
2 Citations
2.380 Impact Factor

Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas.

Mol Cancer Ther 2002 Sep;1(11):923-7

Laboratoire de Toxicocinétique et Pharmacocinétique, Faculté de Pharmacie, 27, Boulevard Jean Moulin, 13385 Marseille, France.

View Article

Download full-text PDF

Source
September 2002
16 Reads
4 Citations
5.683 Impact Factor

Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis.

Biochem Pharmacol 2002 May;63(10):1831-42

UMR CNRS 6032, Faculty of Pharmacy, University of La Méditerranée, 27 Boulevard Jean Moulin, 13005 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(02)00922-xDOI Listing
May 2002
17 Reads
7 Citations
5.010 Impact Factor

Top co-authors

Bruno Lacarelle
Bruno Lacarelle

Aix Marseille University

29
Raphaelle Fanciullino
Raphaelle Fanciullino

School of Pharmacy

19
Cedric Mercier
Cedric Mercier

La Conception University Hospital of Marseille

17
Sarah Giacometti
Sarah Giacometti

Aix Marseille Université

16
Cindy Serdjebi
Cindy Serdjebi

Aix Marseille University

14
Gerard Milano
Gerard Milano

Oncopharmacology Unit

14
Athanassios Iliadis
Athanassios Iliadis

Aix Marseille University

14
Alexandre Evrard
Alexandre Evrard

Laboratoire de biochimie

14
Nicolas Andre
Nicolas Andre

Aix-Marseille University

13
Laetitia Dahan
Laetitia Dahan

Université de la Méditerranée

13